Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Board declares interim dividend of Rs 2 per equity share
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
All India Institute of Ayurveda hosts ministers and showcase their achievements
The company expects revenue growth of 10-15 per cent in the US
Subscribe To Our Newsletter & Stay Updated
